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opyright © 2018 Woltersa,b a,b b aAdriano Taddeo , Catherine Tsai , Esther Vo¨gelin , and Robert RiebenPurpose of review
The long-term adverse effects of immunosuppressive treatment, the high rate of acute rejection and the
development of chronic rejection are the main factors preventing a wider clinical application of
vascularized composite allotransplantation (VCA). Targeted immunosuppression using innovative drug
delivery systems (DDS) may help to overcome these hurdles, increasing therapeutic efficacy while reducing
systemic toxicity. This review provides a summary of the recently developed strategies for targeted delivery
of immunosuppressive drugs in VCA.
Recent findings
Currently, several innovative strategies for targeted immunosuppression have been designed based on the
anatomy and function of the target organ. Site-specific DDS have been developed both for directly
accessible organs (i.e. skin, eye and lung) and internal organs (i.e. lymph nodes, liver, nervous system,
etc.). In preclinical models, DDS designed for sustained, ‘on demand,’ or ‘on cue’ drug release has been
shown to promote VCA survival while reducing systemic toxicity. These findings suggest that targeted
delivery could increase patient compliance and potentially decrease toxicity in VCA recipients.
Summary
Targeted immunosuppression in VCA represents a promising approach for improving patient compliance
and graft survival while reducing off-target toxicity, intensity and frequency of acute rejection episodes and
risk of chronic rejection.
Video Abstract
http://links.lww.com/COOT/A1
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Curr Opin Organ Transplant 2018, 23:000–000
DOI:10.1097/MOT.0000000000000564Vascularized composite allotransplantation (VCA) is
an increasingly performed reconstructive procedure
to restore the appearance, anatomy and function in
patients sufferingmajor tissue loss andnot candidates
for conventional reconstruction [1–3]. The success
achieved in upper extremity and face transplantation
has fueled a rapid expansion of the VCA field and a
host of other types of VCA being performed around
the world, including transplantation of abdominal
wall, bone and joint, laryngotrachea, uterus, penis,
tongue, ear, scalp and lower extremity [4].
Long-term adverse effects, however, of immu-
nosuppressive treatment (IST) are the main factors
preventing a wider clinical application of VCA.
Chronic immunosuppression using this protocol is
associated with diabetes mellitus, nephrotoxicity,rs Kluwer Health, Inc. All rights rese
 Kluwer Health, Inc. Unaemia, opportunistic infections, higher cancer risk as
well as psychological sequelae and increased finan-
cial burden [3,5]. Moreover, a high rate of acute
rejection, with 88% of the patients experiencing at
least one episode in the first posttransplant year [6
&
],
and development of chronic rejection [7] leading torved. www.co-transplantation.com
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KEY POINTS
 Targeted drug delivery systems can increase the
therapeutic index in VCA.
 Implantable and nanocarrier-based drug delivery
systems have shown promising results for site-specific
immunosuppression in skin, eye, lung and
lymph nodes.
 On demand, inflammatory-responsive hydrogels
represent a promising therapeutic approach for the
treatment of inflammatory disease and VCA rejection.
 Sustained site-specific immunosuppression can reduce
side effects increasing patient compliance.
 Validation of targeted immunosuppression: exploration
in large animal models is urgently required.
Composite tissue transplantation
Copgraft vasculopathy and often to graft loss, are others
major problems in VCA management that strongly
decrease the risk-to-benefit ratio of this procedure.
Several strategies have been investigated to
boost the therapeutic index of immunosuppression
(i.e. increasing efficacy and reducing toxicity).
Among them, the development of drug delivery
systems (DDS) has been relentlessly investigated
and a plethora of DDS have been described for
controlled drug release, enhanced bioavailability
and selective organ targeting [8,9]. Due to its acces-
sibility, VCA offers unique opportunities for site-
specific delivery of immunosuppressivemedications
directly to the graft [10]. The rationale for such site-
specific, transplant-targeted IST is to reduce sys-
temic exposure and global collateral or end-organ
adverse effects. Moreover, site-specific treatment
may be used to increase patient compliance. Finally,
because of the high availability of immunosuppres-
sive drug where needed, targeted IST can reduce the
number of systemic drugs required for desired effi-
cacy, as well as the dose and frequency of IST.
In this review, wewill summarize recently devel-
oped strategies for targeted delivery of immunosup-
pressive drugs. We will start by describing DDS
developed for inflammatory diseases and solid
organ transplantation (SOT) and will then focus
on DDS developed specifically for targeted delivery
in VCA.TARGETED IMMUNOSUPPRESSION IN
SOLID ORGAN TRANSPLANTATION AND
INFLAMMATORY DISEASES
Several DDS for delivery of IST have been described
in the fields of inflammatory disease and transplan-
tation. An overview is presented in Tables 1 and 2.2 www.co-transplantation.com
yright © 2018 Wolters Kluwer Health, Inc. UnautReaders are directed to recent reviews that compre-
hensively describe the different strategies for drug
delivery [54–56].
Strategies for targeted delivery should always be
designed based on the anatomy and function of the
target organ. Indeed, organs such as the skin, the eye
or the lung offer unique opportunities for targeted
delivery (e.g. topical administration, eye drops,
inhalation of aerosolized medication). Conversely,
visceral organs such as the liver, lymph nodes and
kidney require DDS containing specific targeting
moieties capable of directing the DDS to the target
organ after systemic application.
Site-specific administration of IST has a long
history in the management of inflammatory skin
disease [57]. Considering that the skin represents
the primary target in VCA rejection [58], DDS devel-
oped for targeted IST delivery in the skin are of
outstanding interest to the VCA community. Several
topical formulations of calcineurin inhibitors have
been described so far and include Food and Drug
Administration (FDA)-approved commercial formu-
lations such as tacrolimus ointment, pimecrolimus
cream and clobetasol propionate cream [10].
Recently, innovative nanocarrier-based topical for-
mulations of tacrolimus have been developed with
the aim to increase skin penetration while reducing
systemic exposure. Topical application of a lipo-
somal tacrolimus formulation has been shown to
increase drug availability in the skin and delay skin
allograft rejection in a mouse model [11]. In addi-
tion, smart DDS that are able to respond to the tissue
environment have been described for IST delivery
into the skin. Thermoresponsive nanogels loaded
with tacrolimus [37,38] or pH-sensitive dexametha-
sone-loaded nanoparticles [16
&&
] are only some of
the examples showing improved skin penetration
and efficacy.
Similar to the skin, the eye and the lung offer the
possibility to use topical application for targeted
delivery of immunosuppressive drugs. Topical instil-
lation of eye drops, intravitreal delivery methods
and periocular routes of drug delivery are some of
the described routes for targeted delivery of medi-
cations directly to the eye [41
&
]. Moreover, intra-
ocular implantable DDS for targeted delivery of
dexamethasone [59,60] and other corticosteroids
[41
&
] as well as tacrolimus [42] have been developed
and are used in a wide range of chronic ocular
inflammatory diseases to deliver drugs in a sustained
fashion. Aerosolized calcineurin inhibitors have
been developed and their efficacy has been tested
in clinical trials. Although these formulations failed
to show efficacy in disease-free survival or overall
mortality, high concentration of the drug was
observed in the lung with minimal systemicVolume 23  Number 00  Month 2018
horized reproduction of this article is prohibited.
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Table 2. Targeted immunosuppression using controlled delivery systems and special formulations in solid organ
transplantations and inflammatory diseases
DDS description
Target organ
(mechanism)
Immuno-suppressive
drug
Testing
model
DDS
administration Reference
Polyglycerol-based
thermoresponsive
nanogels
Skin (site-specific
administration)
Dexamethasone or
Tacrolimus
In-vitro human
skin
Topical
application
[37,38]
PLC microfilms Eye (site-specific
administration)
Prednisolone acetate or
Tacrolimus
Rat corneal
transplantation
Mouse allergic
conjunctivitis
Subconjunctival
implanted
[39,40]
Intravitreal implants
(various formulations)
Eye (site-specific
administration)
Corticosteroids In clinical use Intravitreal
implant
[41&]
PLGA scleral plug Eye (site-specific
administration)
Tacrolimus Rabbit uveitis Intravitreal
implant
[42]
Propylene glycol
suspension
Lung (site-specific
administration)
Cyclosporine Human clinical
trial
Inhalation [43,44,45]
3D-macroporous
polydimethylsiloxane
(PDMS) scaffold
Pancreatic islets
(site-specific administration)
Dexamethasone Diabetic mouse
model
Seeding of the
islets on the
scaffold
[46]
Fibrin gel reservoirs
containing solubilized,
particulated, and
PLGA-microspheres-
encapsulated drug
Peripheral nerve
(site-specific administration)
Tacrolimus In-vitro neurite
extension
In-vitro culture [47]
Electrospun poly(ester
urethane) urea and
tacrolimus elastomeric
matrix (PEUU-Tac)
Central nervous system
(site-specific administration)
Tacrolimus Rat acute central
nervous system
ischemia
Wrapped and
sutured around
the nerve
injury
[48&&]
Ascorbyl palmitate
inflammation-targeting
hydrogel
Inflammation (negative surface
charge to facilitate adhesion
to the positively charged
inflamed colon epithelium)
Dexamethasone Mouse colitis
models
Rectal
administration
[49]
Triglycerol monostearate
inflammation-responsive
hydrogel
Joint (site-specific
administration)
Triamcinolone
acetonide
Mouse
inflammatory
arthritis
Intra-articular
injection
[50&&]
Ointment and cream Skin (site-specific
administration)
Tacrolimus or
pimecrolimus or
clobetasol propionate
Clinical use Topical
application
[10]
Inhalation solution Lung (site-specific
administration)
Tacrolimus Rat lung allograft Inhalation [51]
Nanostructured aggregates Lung (site-specific
administration)
Tacrolimus Rat lung allograft Inhalation [52]
Solutions and ointment Eye (site-specific
administration)
Tacrolimus or
Cyclosporine
Clinical Topical
application
[53]
PEG, poly(ethylene glycol); PLC, poly(D,L-lactide-co-e-caprolactone); PLGA, poly(lactide-co-glycolide); PPS, poly(propylene sulfide).
Composite tissue transplantation
Copexposure [43–45]. Furthermore, encouraging results
have been obtained in preclinical models for the
prevention of acute lung rejection using inhalation
[51] of nanostructured aggregates [52] of tacrolimus.
Although DDS specifically designed for IST targeting
the eye and lung may have limited applications in
upperextremityand face transplantations, these stud-
ies have shown that site-specific immunosuppression
is an effective method to control allograft rejection
providing newmeans and ideas for the generation of
innovative DDS in other VCA procedures.4 www.co-transplantation.com
yright © 2018 Wolters Kluwer Health, Inc. UnautDraining lymph nodes are the main site of
immune activation after transplantation. Therefore,
many studies have focused on delivering IST directly
to the lymphatic system and to the draining lymph
node [61
&&
]. Passive accumulation of nanoparticles
ormicroparticles into the lymph node after systemic
administration (i.e. subcutaneous, intravenous or
intraperitoneal injections) has been reported by
several groups [24,25,62]. Shirali et al. [24] devel-
oped poly-lactide-co-glycolide (PLGA) nanopar-
ticles loaded with mycophenolic acid (MPA) thatVolume 23  Number 00  Month 2018
horized reproduction of this article is prohibited.
CE: Tripti; MOT/230505; Total nos of Pages: 9;
MOT 230505
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Caccumulated into the lymph node prolonging
murine skin allograft survival without detectable
toxicity. Dane et al. [26] demonstrated that encap-
sulated tacrolimus and rapamycin inside micelles
drain to the lymph nodes following intradermal
injection and promote allograft survival in an allo-
geneic skin transplantation model. In order to
improve the trafficking of nanoparticles to lymph
nodes, Azzi et al. [28] designed microparticles con-
taining tacrolimus coated with an anti-MECA-79
antibody for specific delivery to lymph node. Treat-
ment using these microparticles achieved prolonga-
tion of heart allograft survival with low circulatory
levels of tacrolimus. At present, to the best of our
knowledge, none of these targeted IST delivery
modalities to the lymphatic system have been inves-
tigated in VCA models.
Site-specific delivery of tacrolimus has also been
investigated as a means to provide protective and
regenerative benefits to neurons. Fibrin hydrogel
reservoirs containing solubilized, particulateor PLGA
microsphere-encapsulated tacrolimus could be uti-
lized for enhancing peripheral nerve regeneration as
shownby in-vitro dorsal root ganglionneurite exten-
sion assays [47]. The beneficial effect of locally deliv-
ered tacrolimushas recentlybeenconfirmed in vivo. A
biodegradable and elastic matrix of poly(ester ure-
thane) urea (PEUU)-loaded tacrolimus wrapped
around the nerve injurywas shown to decrease astro-
gliosis and increase axon growth signaling pathways,
confirming the potential of site-specific delivery of
tacrolimus to improvenerve repairwhileminimizing
adverse side effects [48
&&
]. The beneficial effect of
locally delivered tacrolimus on nerve regeneration
may contribute to the process of neural repair after
VCA. As functional recovery is one of the most
important determinants of clinical success in VCA,
more studies are warranted to investigate this
intriguing possibility.
’Smart’ materials that can respond to environ-
mental stimuli such as biological signals, patholog-
ical abnormalities or exogenous signals are
appealing therapeutic platforms for targeted IST
delivery [63]. Considering that inflammation is a
driving force for many chronic diseases, inflamma-
tion-responsive hydrogels represent an ideal candi-
date for such a material. It has been demonstrated
that ascorbyl palmitate hydrogels loadedwith dexa-
methasone have preferential adhesion to inflamed
epithelial surfaces and result in a significant reduc-
tion of inflammation with lower drug serum con-
centrations in murine colitis models [49]. More
recently, the same group reported the development
of a triglycerol monostearate hydrogel loaded with
triamcinolone acetonide, demonstrating inflam-
mation-dependent disassembly and reduction of1087-2418 Copyright  2018 Wolters Kluwer Health, Inc. All rights rese
opyright © 2018 Wolters Kluwer Health, Inc. Unaarthritis activity in a mouse model [50
&&
]. These
reports confirm that inflammation-responsive
hydrogels are promising next-generation DDS for
the treatment of inflammatory diseases and
transplant rejection.TARGETED IMMUNOSUPPRESSION IN
VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION
VCA is still a young field in transplantation. After an
initial phase in which the experience gained in SOT
was the driving force for improving outcomes in
VCA patients, researchers have started to develop
VCA-specific strategies to address specific problems
presented by composite grafts. Immunosuppression
obviously represents one of the most pressing issues
in VCA [64]. Consequently, the field has started to
develop approaches for targeted IST (Fig. 1) using
the argument that these highly visible grafts allow
easy monitoring of rejection episodes and provide
the ideal setting for the use of site-specific immuno-
suppression [65].
Data generated in rodent models suggest that
topical tacrolimus [66,67] and clobetasol [67], can
prolong survival without systemic levels of immu-
nosuppressive drugs. Tacrolimus and clobetasol
ointments are already used clinically in episodes
of acute rejection [6
&
]. A topical formulation of
MPA with high local but low systemic exposure in
patients has recently been reported, further expand-
ing the options for topical application of IST in VCA
[68]. A drawback of using ointments and creams in
the clinical setting is the twice-daily application that
demands high patient compliance. Moreover, the
skin penetration of ointments is limited and there
are no commercially available topical formulations
of widely used drugs such as rapamycin [10]. There-
fore, although topical applications can be helpful in
the immediate treatment of acute rejection epi-
sodes, their use as an alternative to systemic immu-
nosuppression is unlikely.
Recently, our group reported that an intra-graft
injection of high-dose tacrolimus may induce long-
term survival with half of the treatment group of rats
reaching 200 days’ survival without signs of rejec-
tion [69]. Intra-graft tacrolimus application imme-
diately after transplantation increased tissue drug
availability, promoting the establishment of tran-
sient donor-cell chimerism and thus long-term graft
acceptance. Recently, the beneficial effect of peri-
transplant high-dose tacrolimus for VCA survival
have also been reported in a swine model [70].
In an earlier work, our group reported the use of
an innovative DDS to achieve long-term (>100
days) VCA survival with reduced systemic exposurerved. www.co-transplantation.com 5
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FIGURE 1. Targeted immunosuppression in vascularized composite allotransplantation. Drug delivery systems specifically
developed for the control of VCA rejection. All the delivery systems described so far have the skin as the main target tissue.
Targeting mechanisms are reported in the bracket. Topical application of tacrolimus cream and ointment has been reported for
immediate, local release of the immunosuppressive drug. Intra-graft injection of tacrolimus in the peri-transplant period
increased drug availability and improves graft survival. An implantable disk containing tacrolimus-loaded microparticles has
been designed for sustained drug release into the graft and draining lymph nodes. Tacrolimus-containing hydrogels (TGMS-
TAC) represent ‘on-demand’ delivery systems that can release the drug in response to inflammatory enzymes, indefinitely
prolonging graft survival with marked reduction of systemic immunosuppression toxicity. Ultrasound responsive alginate-gels
guarantee sustained baseline and ‘on-demand’ release of drugs upon ultrasound stimulation. Low-dose delivery of rapamycin
for controlling rejection and inducing immunoregulatory mechanisms has been achieved using in-situ forming implants.
Figure design by Catherine Tsai. VCA, vascularized composite allotransplantation.
Composite tissue transplantation
Copin a rat model [71]. We demonstrated that trigly-
cerol monostearate (TGMS), an agent generally rec-
ognized as well tolerated by the FDA, could self-
assemble into hydrogels and disassemble in
response to proteolytic enzymes that are over-
expressed during inflammation, providing ‘on-
demand’ drug release. Building upon this study,
we recently investigated the long-term outcomes
and the immunological and toxicological impacts
of this approach [72
&&
]. Our data showed that peri-
odic TGMS loaded with tacrolimus (TGMA-TAC)
injections (every 70 days) promoted long-term graft
survival up to 280 days. Systemic drug exposure was
significantly reduced and TGMS-TAC-treated rats
showed decreased toxicity compared with systemic
tacrolimus-treated rats, the latter group showing
increased creatinine, increased blood urea nitrogen
levels, appearance of opportunistic infections and
aggressive tumors. These results clearly show the
advantages of our ‘on-demand’ release system for
the reduction of immunosuppression toxicity.6 www.co-transplantation.com
yright © 2018 Wolters Kluwer Health, Inc. UnautHowever, while providing better recipient out-
comes, TGMS-TAC treatment resulted in inferior
graft outcomes with TGMS-TAC-treated rats
experiencing at least one rejection episode. There-
fore, further studies are warranted to understand if
these rejections are because of low intra-graft tacro-
limus levels, and if they can be avoided by increas-
ing frequency or dose of the ‘on-demand’ DDS.
The Pittsburg group recently developed a biode-
gradable disk containing tacrolimus-loaded micro-
spheres for sustained regional immunosuppression
in VCA [73
&&
]. As the disk slowly degrades, tacroli-
mus-laden microspheres are released to act in solu-
tion or are actively broken down and phagocytosed
by macrophages. The published results showed sus-
tained tacrolimus release from the disk with steady
systemic levels and significant accumulation of
tacrolimus in the groin lymph nodes. A single injec-
tion of the tacrolimus disk in hind limb-trans-
planted rats promoted allograft survival for more
than 180 days. Moreover, as compared with TGMS-Volume 23  Number 00  Month 2018
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CTAC, burst release of tacrolimus was reduced in
animals injected with the tacrolimus disk. However,
long-term graft outcomes and the toxicity profile of
this sustained-release DDS were not explored.
The same group has recently presented an
abstract describing the development of a DDS drug
that not only provides sustained IST release but also
‘on-cue’ triggered drug release upon ultrasound
stimulation (USS) [74]. The study reported that algi-
nate gels loaded with tacrolimus, rapamycin or
both, released the immunosuppressive drug in
response to USS. When used in vivo in a rat model
of hind limb transplantation, alginate gels pro-
moted long-term allograft survival (>100 days) in
rats receiving tacrolimus-containing gels. However,
although concentration in allograft tissues was
higher than in the blood and the contralateral limb,
sustained drug release occurred from alginate gels in
the absence of ultrasound, prompting the authors to
devote further efforts to optimizing the on-cue
drug release.
The potential of locally delivered immunosup-
pression to promote VCA survival has also led us to
investigate whether the administration of immuno-
suppressive drugs directly into the graft may reduce
potential side effects as well as directly influence the
magnitude and nature of an allogeneic immune
response. We have designed an in-situ forming
implant (ISFI) loaded with the immunoregulatory
drug rapamycin [75]. A single injection of the rapa-
mycin-loaded ISFI (Rapa-ISFI) in close proximity to
the transplant prolonged VCA survival up to 100
days. Importantly, rats treated with Rapa-ISFI had
significantly higher levels of multilineage chime-
rism and Treg in peripheral blood and transplanted
skin compared with untreated rats. This study dem-
onstrates that targeted IST delivery can be used not
only to promote less toxic immunosuppressive pro-
tocols and patient compliance but also to favor the
reprogramming of the local response toward
regulatory function.LIMITATIONS AND FUTURE
PERSPECTIVES
All these preclinical experiments confirm that site-
specific immunosuppression is a feasible and prom-
ising approach in VCA. However, thus far the suc-
cess of this therapeutic approach has been proven
only in rodent models. Targeted IST therapies need
to be validated in large animal models that generate
solid preclinical data in order to substantiate the
notion that targeted immunosuppression has real
advantages in VCA. Evaluation of long-term graft
and toxicity outcomes should be the main focus.
Moreover, in order to determine the right dose of1087-2418 Copyright  2018 Wolters Kluwer Health, Inc. All rights rese
opyright © 2018 Wolters Kluwer Health, Inc. Unalocal immunosuppression needed, more efforts
should be devoted to building a graft-specific ‘ther-
apeutic window’ rather than relying on systemic
drug levels.
On the other hand,multidrug immunosuppres-
sive protocols are currently used in human patients
to guarantee an effective level of immunosuppres-
sion. Therefore, localized immunosuppression
should further evolve to include multiple drugs to
control graft rejection. Eventually, combined use of
minimized systemic immunosuppression and tar-
geted immunosuppression might be envisaged to
balance graft and toxicity outcomes.
Importantly, despite promising results, limita-
tions associated with implantable DDS such as
foreign body reaction, pro-inflammatory microen-
vironment promoted by the biomaterials,
activation of the complement system and immu-
nogenicity, particularly following consecutive
implantations, should be carefully evaluated in
specifically designed studies.CONCLUSION
Targeted immunosuppression in VCA represents a
promising new approach for improving patient
compliance and graft survival while reducing off-
target toxicity, intensity and frequency of acute
rejection episodes and risk of chronic rejection.
More studies are needed to generate solid preclinical
data on the modalities of application, drug-distribu-
tion, toxicity profile and immunological parameters
of DDS-based approaches. Such studies will foster
the development of effective delivery platforms,
paving the way for the design of clinical trials in
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